Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Honigman says it represents Catalio in Evvy’s $40 million Series B
Honigman announced that it had represented Catalio Capital Management as lead investor in Evvy’s $40 million Series B financing. The firm described Catalio as a healthcare-focused investor and Evvy as a women’s health platform serving patients across the United States and working with healthcare providers.
Key points
- Honigman named Phillip Torrence and Rachel Rhodes as the lead corporate partners.Honigman
- The firm said associate Aaron Katz supported the team.Honigman
- Honigman described Evvy’s platform as combining diagnostic testing with clinical insights.Honigman
- The announcement said the platform also provided care recommendations.Honigman